SCHEMBL6490043

SCHEMBL6490043

CCOc1ccccc1Oc1c(Cl)nc(-c2nccc(C(N)=O)n2)nc1C(N)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ RXFP1 Q9HBX9 2/20 0.39
▸ USP2 O75604 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ DHPS P49366 8/20 0.37
▸ ALPL P05186 1/20 0.37
▸ ALPI P09923 1/20 0.37
▸ ALPG P10696 1/20 0.37
▸ SCN9A Q15858 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5097958 0.91 KDM4E (0.42) KDM4EMEN1KMT2ARXFP1USP2
SCHEMBL4062097 0.80 DHPS (0.51) DHPS
SCHEMBL7853937 0.77 DHPS (0.57) DHPS
SCHEMBL7851035 0.76 EDNRA (0.48) DHPS
SCHEMBL5097965 0.73 DHPS (0.56) DHPSALDH1A1
SCHEMBL4061451 0.72 DHPS (0.58) DHPS
SCHEMBL7698526 0.71 DHPS (0.46) DHPS
SCHEMBL7850706 0.71 EDNRA (0.52) DHPSNPC1RAB9A
SCHEMBL5036558 0.69 DHPS (0.48) DHPS
SCHEMBL27569268 0.69 L3MBTL1 (0.47) KDM4EMEN1KMT2ARXFP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050085639-A1 Novel alkansulfonamides as endothelin antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2005-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085639-A1 Novel alkansulfonamides as endothelin antagonists EDNRA, EDNRB, ECE1 KDM4E 916/4885MEN1 2660/4885KMT2A 3592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback